Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study

Pediatrics
Sheila F FriedlanderTinea Capitis Study Group

Abstract

Terbinafine has been shown to be effective in tinea capitis, using different treatment durations. However, no direct comparison of treatment duration has previously been investigated. This randomized, double-blind, parallel-group, multicenter study was designed to assess the effect of terbinafine treatment duration on the outcome of Trichophyton tinea capitis in a North American population. A total of 176 patients with a clinical diagnosis of tinea capitis were enrolled in this study and treated with oral terbinafine (3-6 mg/kg/d) for 1, 2, or 4 weeks. All patients were to be followed until week 12. A total of 159 patients had culture-confirmed tinea capitis attributable to Trichophyton species and constituted the intent-to-treat population used for efficacy analysis (50, 55, and 54 patients in the 1-, 2-, and 4-week arms, respectively). At the end of study, effective treatment, defined as negative culture and low scores on signs and symptoms, was achieved in 56%, 69%, and 65% of patients who were treated with terbinafine for 1, 2, and 4 weeks, respectively. A negative culture was achieved in 60%, 76%, and 72%, respectively. Overall, the efficacy data showed that both the 2- and 4-week treatment regimens are clinically superior...Continue Reading

References

Feb 1, 1992·The British Journal of Dermatology·M J Goodfield
Jul 1, 1995·Archives of Pediatrics & Adolescent Medicine·T G GivensR C Baker
May 1, 1996·Mycoses·E GruseckD Abeck
Apr 1, 1997·The Annals of Pharmacotherapy·S M Abdel-RahmanD A Powell
Aug 1, 1997·Journal of the American Academy of Dermatology·P KullavanijayaR Ungpakorn
Feb 27, 1999·The Pediatric Infectious Disease Journal·R Aly
Jul 20, 1999·Journal of the American Academy of Dermatology·B Krafchik, J Pelletier
Aug 10, 1999·Drugs·K J McClellanA Markham
Dec 22, 1999·Journal of the American Academy of Dermatology·H Cáceres-RíosB Bustamante
Sep 7, 2000·Medical Mycology·A K Gupta, R C Summerbell

❮ Previous
Next ❯

Citations

Feb 3, 2005·Medical Mycology·Jenny HällgrenCarl-Fredrik Wahlgren
Mar 17, 2004·Current Opinion in Infectious Diseases·Yuin-Chew Chan, Sheila Fallon Friedlander
Oct 13, 2005·The Pediatric Infectious Disease Journal·Susan M Abdel-RahmanGilles-Jacques Rivière
Sep 19, 2007·Pediatric Emergency Care·Samina AliSarah E D Forgie
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Jason G Newland, Susan M Abdel-Rahman
Aug 11, 2004·American Journal of Clinical Dermatology·Aditya K GuptaMaria M Chaudhry
Dec 25, 2002·Antimicrobial Agents and Chemotherapy·Pranab K MukherjeeMahmoud A Ghannoum
Mar 19, 2014·Pediatric Clinics of North America·Leslie Castelo-Soccio
May 18, 2013·Journal of the American Academy of Dermatology·Howard B PrideRobert Silverman
Mar 29, 2005·Pediatric Annals·Brandie J Roberts, Sheila Fallon Friedlander
Dec 22, 2015·Clinics in Dermatology·Lynne J Goldberg, Leslie A Castelo-Soccio
Dec 22, 2015·Clinics in Dermatology·Shehla AdmaniBrett Sloan
Jan 26, 2007·Advances in Dermatology·Daniel S Loo
Nov 12, 2005·Skinmed·Aditya K GuptaElizabeth A Cooper
May 3, 2007·Mycoses·C SeebacherUNKNOWN German Hospital Hygiene Society
Dec 21, 2006·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Claus SeebacherHans-Jrgen Tietz
Dec 17, 2009·Mycoses·Gopal A Patel, Robert A Schwartz
Oct 26, 2010·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Gabriele Ginter-Hanselmayer, Claus Seebacher
Sep 23, 2014·The British Journal of Dermatology·L C FullerE M Higgins
Oct 26, 2005·Journal of the American Academy of Dermatology·K Wade FosterBoni E Elewski
Sep 6, 2003·Dermatologic Clinics·Aditya K GuptaCharles W Lynde
Mar 5, 2004·Expert Opinion on Pharmacotherapy·Yuin-Chew Chan, Sheila F Friedlander
Jul 1, 2009·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Ali M SabzghabaeeMahboobeh Mohammadi
Nov 7, 2016·Journal of the American Academy of Dermatology·Xiaomei ChenMin Zhang
Mar 17, 2004·Dermatologic Clinics·Daniel S Loo
Jun 3, 2009·Clinical Pediatrics·Kelly C Lorch DaukLydia M Furman
Feb 6, 2004·Journal of the European Academy of Dermatology and Venereology : JEADV·A K GuptaE A Cooper
Jul 31, 2004·Pediatric Dermatology·Gabriele Ginter-HanselmayerAditya Gupta
Feb 7, 2020·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Peter MayserMiriam Zidane
Feb 7, 2020·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Peter MayserMiriam Zidane
May 14, 2016·The Cochrane Database of Systematic Reviews·Xiaomei ChenCathy Bennett
May 26, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·A K GuptaS F Friedlander
May 15, 2008·Mycopathologia·Aditya K Gupta, Elizabeth A Cooper
Sep 27, 2020·The Journal of Dermatology·Takashi MochizukiUNKNOWN Guidelines Committee of the Japanese Dermatological Association
Sep 28, 2017·Pediatrics·H Dele DaviesUNKNOWN COUNCIL ON SPORTS MEDICINE AND FITNESS

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.